{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:14:06Z","timestamp":1772219646105,"version":"3.50.1"},"reference-count":21,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Data on the safety of coronavirus disease 19 (COVID-19) vaccines in gynecologic cancer patients are scarce. The type of vaccine used in Thailand differs from what has been studied in other countries. This study evaluated the prevalence and characteristics of reported adverse events following COVID-19 vaccines in patients with gynecologic cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A retrospective, single-center descriptive study was performed in patients with gynecologic cancer who received at least one dose of the COVID-19 vaccine at King Chulalongkorn Memorial Hospital, Thailand, from January 2020 to August 2021. Adverse events were collected through structured telephone interviews using a standardized questionnaire. Descriptive statistics summarized patient characteristics and adverse events. Associations with any-grade adverse events were assessed using logistic regression and Fisher\u2019s exact test for categorical variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 294 patients interviewed, 72.8% were in remission, under surveillance, or in palliative treatment at the time of vaccination, and 17.7% were undergoing treatment. The most common adverse effects were grade 1\u20132 injection site reactions. One patient developed grade 3 fever and seizures 10 days after the first dose of the AstraZeneca vaccine. Between the second and fourth doses of the vaccination, the most common adverse events were grade 1\u20132 injection site reactions. No severe allergic reactions or grade 4 adverse events were reported. The study concluded that patients under 60 years of age had more adverse events than older patients (adjusted odds ratio 1.99, 95% confidence interval 1.08\u20133.71 p\u2009=\u20090.029). The treatment status did not affect adverse events. Of 283 patients who received two doses, 27.6% were infected with COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>COVID-19 vaccination was generally well tolerated among gynecological cancer patients who received active anticancer therapy and those under surveillance. Younger patients frequently reported more adverse effects than older patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0342303","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:31:43Z","timestamp":1772217103000},"page":"e0342303","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reported adverse events following COVID-19 vaccination in gynecologic cancer patients in Thailand: A descriptive study"],"prefix":"10.1371","volume":"21","author":[{"given":"Sasivimon","family":"Ratree","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5553-1783","authenticated-orcid":true,"given":"Nicha","family":"Assavapokee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somsook","family":"Santibenchakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakarin","family":"Sirisabya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waranyoo","family":"Phoolcharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-7740","authenticated-orcid":true,"given":"Natacha","family":"Phoolcharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"pone.0342303.ref001","unstructured":"World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard: Global situation. 2021. Accessed on 15 January 2021."},{"key":"pone.0342303.ref002","doi-asserted-by":"crossref","first-page":"144","DOI":"10.11604\/pamj.supp.2020.35.2.24582","article-title":"Managing cancer patients during COVID-19 pandemic: a North African oncological center experience","volume":"35","author":"YM Ammor","year":"2020","journal-title":"Pan Afr Med J"},{"key":"pone.0342303.ref003","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa439.567","article-title":"372. Comparing the Outcome of COVID-19 in Cancer and Non-Cancer Patients: an International Multicenter Study","volume":"7","author":"RY Hachem","year":"2020","journal-title":"Open Forum Infectious Diseases"},{"issue":"27","key":"pone.0342303.ref004","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"FP Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"10269","key":"pone.0342303.ref005","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"M Voysey","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"pone.0342303.ref006","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"LR Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0342303.ref007","article-title":"Analysis of People\u2019s Attitude Toward COVID-19 Vaccine and Its Information Sources in Thailand","volume":"14","author":"T Yoda","year":"2022","journal-title":"Cureus"},{"key":"pone.0342303.ref008","unstructured":"Centers for Disease Control and Prevention. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine. https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/pfizer\/reactogenicity.html 2022. 2022 May 17."},{"issue":"10267","key":"pone.0342303.ref009","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"MN Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"pone.0342303.ref010","doi-asserted-by":"crossref","first-page":"577661","DOI":"10.1016\/j.jneuroim.2021.577661","article-title":"Hyperacute reversible encephalopathy related to cytokine storm following COVID-19 vaccine","volume":"358","author":"L Baldelli","year":"2021","journal-title":"J Neuroimmunol"},{"key":"pone.0342303.ref011","doi-asserted-by":"crossref","first-page":"577629","DOI":"10.1016\/j.jneuroim.2021.577629","article-title":"New-onset refractory status epilepticus following the ChAdOx1 nCoV-19 vaccine","volume":"357","author":"Y Aladdin","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"3","key":"pone.0342303.ref012","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.dsx.2021.05.003","article-title":"Focal onset non-motor seizure following COVID-19 vaccination: A mere coincidence?","volume":"15","author":"R Ghosh","year":"2021","journal-title":"Diabetes Metab Syndr"},{"issue":"7","key":"pone.0342303.ref013","article-title":"Two Cases of Post-Moderna COVID-19 Vaccine Encephalopathy Associated With Nonconvulsive Status Epilepticus","volume":"13","author":"BD Liu","year":"2021","journal-title":"Cureus"},{"key":"pone.0342303.ref014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jocn.2023.03.008","article-title":"Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review","volume":"111","author":"F Nabizadeh","year":"2023","journal-title":"J Clin Neurosci"},{"key":"pone.0342303.ref015","doi-asserted-by":"crossref","first-page":"100983","DOI":"10.1016\/j.cegh.2022.100983","article-title":"Incidence and severity of SARS-CoV-2 virus post COVID-19 vaccination: A cross-sectional study in India","volume":"14","author":"P Selvaraj","year":"2022","journal-title":"Clin Epidemiol Glob Health"},{"issue":"1","key":"pone.0342303.ref016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"S Xia","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"pone.0342303.ref017","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/1097-0142(19840615)53:12<2619::AID-CNCR2820531209>3.0.CO;2-D","article-title":"Effect on immunologic and other indices of adjuvant cytotoxic chemotherapy including melphalan in breast cancer","volume":"53","author":"IR Mackay","year":"1984","journal-title":"Cancer"},{"issue":"1","key":"pone.0342303.ref018","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-015-0669-x","article-title":"Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer","volume":"18","author":"R Verma","year":"2016","journal-title":"Breast Cancer Res"},{"issue":"2","key":"pone.0342303.ref019","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028561","article-title":"Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study","volume":"101","author":"W Kian","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"pone.0342303.ref020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12885-020-6667-0","article-title":"Guy\u2019s cancer cohort - real world evidence for cancer pathways","volume":"20","author":"C Moss","year":"2020","journal-title":"BMC Cancer"},{"issue":"25","key":"pone.0342303.ref021","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"EE Walsh","year":"2020","journal-title":"N Engl J Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:31:48Z","timestamp":1772217108000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0342303"}},"subtitle":[],"editor":[{"given":"Omnia S.","family":"El Seifi","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0342303","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}